IQVIA conducted a real-world study on treatment pathways and drug persistence for type I and II diabetes patients using OMOP databases. The analysis covered multiple oral antidiabetic drug classes and basal insulin, assessing persistence across six-month selection periods between 2016 and 2021. Persistence outcomes were categorized as persistent, off therapy, restart, switch, or discontinuous over 36 months. Results revealed differences by drug class, age group, and comorbidities, offering insights into treatment journeys. The client leveraged these findings to identify market segment opportunities and adjust drug positioning, enabling more targeted diabetes care strategies.

Join for free to read